Teva Pharmaceuticals Agrees to Settlement in Effexor XR Antitrust Case Over Generic Entry Delay

Teva Pharmaceuticals has reached a settlement with a class of consumers and third-party payers over an antitrust case involving the antidepressant drug Effexor XR. The litigation revolved around accusations that Teva engaged in a scheme to delay the entry of generic versions of the medication into the market. This resolution was detailed in a recent court filing.